{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338022","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2026-08-06T20:11:52+00:00","discovered_at":"2026-08-06T20:13:00.710960+00:00","generated_at":"2026-08-06T20:16:12.462763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed","bullets":["Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.","Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.","Adjusted EBITDA loss $34.4M vs $3.6M loss; operating loss $51.0M vs $12.6M.","FY 2026 revenue guidance cut to $179M-$215M (62-68% decline) from prior 45-52% decline.","Cash $46.8M, no debt; CEO cites slower-than-expected market recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338022","json":"https://secwatch.observer/filing/0001193125-26-338022.json","markdown":"https://secwatch.observer/filing/0001193125-26-338022.md","text":"https://secwatch.observer/filing/0001193125-26-338022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/0001193125-26-338022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/orgo-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:16:12.462763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}